Navigation Links
As Lipitor Lawsuits Mount, Bernstein Liebhard LLP Notes Publication of New Study with Possible Explanation for Link between Statins and Diabetes

New York, New York (PRWEB) January 08, 2014

As Lipitor lawsuits ( continue to mount in courts around the country, Bernstein Liebhard LLP notes the publication of a new study that has found a possible explanation for the link between statins like Lipitor and the development of Type 2 diabetes. The research, which appears in the journal Diabetes, Obesity, and Metabolism, found that some statins may reduce levels of a hormone called adiponectin, which the authors of the study say could result in islet cell dysfunction and insulin resistance. They further point out that only one statin – pitavastatin – has been seen to increase adiponectin levels, and it is the only medication in that class that has not been linked to an increased risk of new-onset diabetes.*

“We are currently investigating a number of legal claims on behalf of individuals who allegedly developed Type 2 diabetes due to their use of Lipitor. This study provides valuable insight regarding the possible mechanism behind their alleged injuries,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Lipitor lawsuit reviews to anyone who may have developed new-onset Type 2 diabetes due to the use of this statin medication.

Lipitor and Diabetes

In January 2012, research published in JAMA: Internal Medicine reported that post-menopausal women treated with drugs like Lipitor were at increased risk of developing new-onset Type 2 diabetes.** A month later, the U.S. Food & Drug Administration (FDA) ordered that new warnings be added to the labels of Lipitor and other statins regarding their possible association with the disease.

In May 2013, a study published in the British Medical Journal confirmed the possible link between Lipitor and diabetes, finding that use of the drug was associated with a 22 percent increased risk of new-onset diabetes.***

Since the FDA issued its alert in February 2012, numerous individuals have filed Lipitor lawsuits that allege their use of the statin resulted in a diagnosis of Type 2 diabetes. According to court documents, the U.S. Judicial Panel will hear oral arguments on January 30th regarding the possible consolidation of federally-filed Lipitor diabetes claims in a single jurisdiction for pretrial proceedings. The hearing will mark the second time the Panel has taken up this matter, as it rejected a previous request from plaintiffs in April on the grounds that there were not sufficient filings to warrant the establishment of a multidistrict litigation. However, in their second request seeking consolidation of Lipitor lawsuits, plaintiffs point out that at least 100 complaints involving diabetes allegations are now pending in federal courts around the country. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502 (JPML))

Individuals who allegedly developed Type 2 diabetes due to their use of Lipitor may be entitled to compensation for medical bills, lost wages, pain and suffering and other damages. To learn more about filing a Lipitor lawsuit, please visit Bernstein Liebhard LLP’s website. To arrange for a free legal review, please call 800-511-5092.

*; Diabetes, Obesity, and Metabolism, December 24, 2013
**, JAMA Internal Medicine, January 2012
***, BMJ, May 2013

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Lipitor Lawsuit News: Bernstein Liebhard LLP Notes Criticism of New Statin Guidelines That Could Result in Millions of New Lipitor Prescriptions
2. New Lipitor Diabetes Lawsuit Alleges Statin Drug Caused Woman to Develop Type 2 Diabetes, Learns Wright & Schulte LLC
3. Lipitor Lawsuits Continue to Mount, as Bernstein Liebhard LLP Notes Filing of New Claim Alleging an Association Between Lipitor and Diabetes
4. Dozens of Lipitor Lawsuits Involving Diabetes Allegations Moved to Federal Court, Bernstein Liebhard LLP Reports
5. Warning of Statin Drug Lipitor’s Risk of Type 2 Diabetes Came Too Late Say Patients Filing Lipitor Lawsuits
6. Lipitor Lawsuit News: Judicial Panel Denies Consolidation of Federal Cases, Rottenstein Law Group LLP Reports
7. Lipitor Lawsuit Website Launched by Bernstein Liebhard LLP to Provide Information to the Public Regarding Lipitor Side Effects, Ongoing Litigation
8. National Law Firm Baron and Budd Helping Women with Alleged Injuries from Lipitor Use Understand the Lipitor Lawsuit
9. National Law Firm Baron and Budd Responds to Disproportionate Harm Brought to Women Using Lipitor, According to Study
10. Lipitor News: Rottenstein Law Group LLP Comments on Boomers’ Favorite Drug
11. Lipitor Lawsuit News: Rottenstein Law Group LLP Responds to Reports of Lipitor Giveaway
Post Your Comments:
(Date:11/24/2015)... , ... November 24, 2015 , ... In an ... restrictions and variables that determine which patients are or are not eligible for bariatric ... have a BMI over 40, are more than 100 pounds overweight, or have a ...
(Date:11/24/2015)... UT (PRWEB) , ... November 24, 2015 , ... It ... Magazine. For a business, it is critical that the first impression be positive and ... they are not likely to buy anything or want to return. They will also ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... gather to share their knowledge and experiences at a live taping of the ... Ruesch Center for the Cure of Gastrointestinal Cancers 2015 Symposium at Georgetown University ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Aided by ... today announced an innovative study designed to yield insights into how to detect and ... of biomarkers for pancreatic cancer from small, non-coding RNA molecules (ncRNA), genetic material that ...
(Date:11/24/2015)... ... November 24, 2015 , ... Sir Grout of Baltimore is ... certification. The award recognizes good companies for excellence in service and a commitment ... and hard surface restoration company earned this recognition after a thorough review by ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... November 24, 2015 F1000Workspace - ... - since it was launched just six months ago. ... and authoring platform for scientists - since it was launched ... have been loaded on to F1000Workspace - a ... since it was launched just six months ago. ...
(Date:11/24/2015)... YORK , Nov. 24, 2015 iRhythm Technologies, ... advancing cardiac care, today announced that it will participate in the ... Hotel in New York, NY . ... present on Tuesday December 1, 2015 at 8:50am ET. ... . --> . ...
(Date:11/24/2015)... uptake of recently approved and pipeline premium products for Type 1 Diabetes ... says GBI Research . --> The ... Mellitus (T1DM), will be a key driver of market growth to 2021, ... The uptake of recently approved and pipeline premium products for Type 1 ... 2021, says GBI Research . Type ...
Breaking Medicine Technology: